UNIVERSITY COLLEGE LONDON
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Private
- Established
- 1826-02-11
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ucl.ac.uk
Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
Phase 1
Withdrawn
- Conditions
- Recurrent Glioblastoma
- Interventions
- Radiation: Re-irradiation (re-RT)
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- University College, London
- Registration Number
- NCT05666349
Electrical Impedance Tomography & Selective Stimulation of Vagus Nerve
Not Applicable
Recruiting
- Conditions
- Vagus Nerve DiseasesVagus Nerve Autonomic DisorderEpilepsy
- Interventions
- Device: Nerve cuff electrodes for spatially selective vagus nerve stimulation and electrical impedance tomography
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- University College, London
- Target Recruit Count
- 50
- Registration Number
- NCT05664854
- Locations
- π¬π§
National Hospital of Neurology and Neurosurgery, London, Greater London, United Kingdom
ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer
Recruiting
- Conditions
- Cancer of ProstateCancer Head NeckCancer Cervix
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- University College, London
- Target Recruit Count
- 990
- Registration Number
- NCT05653063
- Locations
- πΏπ¦
Groote Schuur Hospital, Cape Town, South Africa
π―π΄King Hussein Cancer Center, Amman, Jordan
π²πΎUniversity of Malaya Medical Center, Kuala Lumpur, Malaysia
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
Not Applicable
Recruiting
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- Radiation: Proton beam therapy
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- University College, London
- Target Recruit Count
- 148
- Registration Number
- NCT05655078
- Locations
- π¬π§
Royal Berkshire Hospital, Reading, England, United Kingdom
π¬π§Southend University Hospital, Southend, Essex, United Kingdom
π¬π§Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom
Shaping Care Home COVID-19 Testing Policy
Phase 3
Not yet recruiting
- Conditions
- COVID-19
- Interventions
- Diagnostic Test: Lateral Flow Device
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- University College, London
- Target Recruit Count
- 280
- Registration Number
- NCT05639205
The Efficacy of Chlorella Supplementation on Health and Performance Following a 12-week Training Programme
Not Applicable
Completed
- Conditions
- SedentaryOverweight
- Interventions
- Dietary Supplement: Chlorella supplementationOther: 12 week cardiovascular training programmeDietary Supplement: Placebo Supplementation
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- University College, London
- Target Recruit Count
- 36
- Registration Number
- NCT05639634
- Locations
- π¬π§
University Colllege London (ISEH), London, United Kingdom
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- University College, London
- Target Recruit Count
- 50
- Registration Number
- NCT05635162
- Locations
- π¬π§
Churchill Hospital, Oxford, United Kingdom
π¬π§Derriford Hospital, Plymouth, United Kingdom
π¬π§Southampton General Hospital, Southampton, United Kingdom
Remote Assessment of Lung Disease and Impact on Physical and Mental Health
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary DiseaseInterstitial Lung DiseaseCovid19
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- University College, London
- Target Recruit Count
- 60
- Registration Number
- NCT05630599
- Locations
- π¬π§
Royal Free Hospital, London, United Kingdom
π¬π§University College London Hospital, London, United Kingdom
TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Recruiting
- Conditions
- Small Cell Lung CancerPleural MesotheliomaLung Cancer, Non-small Cell
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- University College, London
- Target Recruit Count
- 600
- Registration Number
- NCT05628376
- Locations
- π¬π§
University College London Hospitals NHS Foundation Trust, London, United Kingdom
Response Adapted Incorporation of Tislelizumab Into the Front-line Treatment of Older Patients With Hodgkin lYmphoma
Phase 2
Not yet recruiting
- Conditions
- Hodgkin Lymphoma
- Interventions
- Drug: Tislelizumab, AVD, Radiotherapy
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- University College, London
- Target Recruit Count
- 80
- Registration Number
- NCT05627115
Β© Copyright 2025. All Rights Reserved by MedPath